{"nctId":"NCT03229057","briefTitle":"Comparing the Effects of Oral Contraceptive Pills Versus Metformin","startDateStruct":{"date":"2018-01-15","type":"ACTUAL"},"conditions":["PCOS"],"count":240,"armGroups":[{"label":"OCP + Placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: OCP + Placebo"]},{"label":"Metformin + Placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Metformin + Placebo"]},{"label":"OCP + Metformin","type":"EXPERIMENTAL","interventionNames":["Drug: OCP + Metformin"]}],"interventions":[{"name":"OCP + Metformin","otherNames":[]},{"name":"OCP + Placebo","otherNames":[]},{"name":"Metformin + Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Women ≥ 18 to ≤ 40 years of age (at the time of screening), with hyperandrogenic PCOS.\n2. Subjects will be diagnosed with PCOS defined by the most recent Rotterdam criteria based on:\n\n   1. androgen excess (defined as an elevated serum T level or hirsutism, based on a Ferriman Gallwey score \\> 8 (note: \\> 2 for women of Asian descent)\n\n      AND either:\n   2. history of chronic anovulation (8 or fewer periods per year)\n\n      AND/OR\n   3. polycystic ovaries.\n3. BMI ≥ 25 kg/m² to ≤ 48 kg/m² obtained at screening visit.\n4. In good general health.\n5. Willing to avoid pregnancy for the duration of the study.\n\nExclusion Criteria:\n\n1. Current pregnancy or desire of pregnancy during course of study\n2. Currently breastfeeding\n3. Known 21 hydroxylase deficiency\n4. Untreated thyroid disease (TSH \\<0.45 mlU/mL and \\> 4.5 mlU/mL)\n5. Untreated hyperprolactinemia (2 Levels\\>30 ng/ml at least one week apart)\n6. Type 1 or type 2 Diabetes Mellitus (elevated fasting serum glucose \\>126mg/dL on two occasions, poorly controlled diabetes (HgbA1C\\>6.5%), currently receiving anti-diabetic agents, or currently receiving metformin for treatment of diabetes\n7. Liver disease (AST/ALT\\>2 times normal or a total bilirubin \\>2.5 mg/dL)\n8. Renal disease (BUN\\>30 mg/dL or serum creatinine \\>1.4 mg/dL)\n9. Anemia (hemoglobin \\<10 mg/dL)\n10. History of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident\n11. Current history of alcohol abuse (\\>14drinks/week)\n12. Poorly controlled hypertension defined as average systolic blood pressure \\>= 150 mm Hg or average diastolic \\>=100 mm Hg obtained on three measurements obtained 5 minutes apart. If treated, average systolic blood pressure \\>=140 mm Hg or average diastolic \\>=90 mm Hg\n13. Patients with a history of, or suspected cervical carcinoma, endometrial carcinoma, or breast carcinoma\n14. TG\\>200mg/dl\n15. Use of lipid lowering or weight loss agents (subjects may wash out from weight loss agents)\n16. Current use of oral contraceptives, depo progestin, or hormonal implants\n17. Participation in any study of an investigational drug or device or biological agent within 30 days\n18. Suspected adrenal or ovarian tumor secreting androgens\n19. Suspected Cushing's syndrome\n20. Bariatric surgery procedure in the recent past (\\<12 months)\n21. Absolute contraindications to the use of hormonal contraceptives or metformin,\n\n23\\. Subjects who are unable to comply with the study procedures, for instance due to mental illness, substance abuse, or participation in other studies.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"40 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Metabolic Syndrome After 6 Months of Treatment Metformin or OCP+Metformin for 6 Months.","description":"Our primary goal is to determine the effect of 6 months' treatment with OCP vs. metformin vs. OCP + metformin on prevalence of MetS and its components in overweight / obese women. Implicit in the primary aim is clearly defining MetS, by NCEP ATPIII criteria as the presence of at least 3 of the following 5 criteria: TG≥150mg/dl, HDL-C\\<50mg/dl, BP≥130/≥85mmHg, WC\\>88cm and fasting glucose≥100mg/dl; and the goal of tracking safety of our interventions at all Phases of the study (through safety lab evaluations, vital signs and diaries)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes in Serum Apoliprotein B From Baseline to 6 Months","description":"This will be measured by NMR spectroscopy","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".03","spread":null},{"groupId":"OG001","value":"0.003","spread":null},{"groupId":"OG002","value":"0.05","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes in Serum Adipokines in the 3 Arms","description":"Serum adipokines to be measured are adiponectin and leptin. These changes will be correlated with changes in serum and androgens and markers of insulin sensitivity","classes":[]},{"type":"SECONDARY","title":"Changes in Total Body Fat Distribution in the 3 Arms From Baseline to 6 Months","description":"Body fat distribution will be measured by DXA. These changes will be correlated with changes in serum and androgens and markers of insulin sensitivity","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.83","spread":null},{"groupId":"OG001","value":"-0.48","spread":null},{"groupId":"OG002","value":"0.06","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes in Total Triglyceride-Rich Lipoprotein (TRLP) From Baseline to 6 Months","description":"This will be measured by NMR spectroscopy","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.26","spread":null},{"groupId":"OG001","value":"6.33","spread":null},{"groupId":"OG002","value":"10.24","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes in Serum Marker of Inflammation: Free Fatty Acids.","description":"Measured by change in Free Fatty Acids","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":null},{"groupId":"OG001","value":"-0.03","spread":null},{"groupId":"OG002","value":"0.09","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes in Quality of Life Parameters for Body Hair in All 3 Arms as Assessed by PCOSQ From Baseline to 6 Months","description":"QOL will be measured by the Polycystic Ovary Syndrome Questionnaire (PCOSQ) Body Hair domain which has 5 items rated on a 7 point likert scale with a lower score representing a decreased quality of life. The total range is 7 to 35.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.74","spread":null},{"groupId":"OG001","value":"0.26","spread":null},{"groupId":"OG002","value":"0.62","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes in Visceral Body Fat Distribution in the 3 Arms","description":"Body fat distribution will be measured by DXA. These changes will be correlated with changes in serum and androgens and markers of insulin sensitivity","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-167","spread":null},{"groupId":"OG001","value":"-86","spread":null},{"groupId":"OG002","value":"-58","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes in Quality of Life Parameters for Weight in All 3 Arms as Assessed by PCOSQ From Baseline to 6 Months","description":"QOL will be measured by the Polycystic Ovary Syndrome Questionnaire (PCOSQ) Weight domain which has 5 items rated on a 7 point likert scale with a lower score representing a decreased quality of life. The total range is 7 to 35.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.72","spread":null},{"groupId":"OG001","value":"0.34","spread":null},{"groupId":"OG002","value":"0.62","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in HDL-C Function","description":"This will be assessed by measuring reverse cholesterol efflux capacity using validated ex vivo system","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":79},"commonTop":["Diarrhea","Nausea","Headache/Migraine","Abdominal Pain/Cramping","Vomiting"]}}}